Patrick Cunningham Sells 18,436 Shares of Aveanna Healthcare (NASDAQ:AVAH) Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) insider Patrick Cunningham sold 18,436 shares of the firm’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $7.21, for a total value of $132,923.56. Following the completion of the transaction, the insider owned 337,755 shares in the company, valued at approximately $2,435,213.55. This trade represents a 5.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Aveanna Healthcare Stock Down 1.1%

AVAH opened at $7.34 on Friday. Aveanna Healthcare Holdings Inc. has a 1 year low of $3.67 and a 1 year high of $10.32. The firm has a 50 day moving average price of $8.45 and a 200 day moving average price of $8.46. The company has a debt-to-equity ratio of 140.39, a quick ratio of 1.23 and a current ratio of 1.23. The company has a market cap of $1.53 billion, a PE ratio of 20.39 and a beta of 2.06.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Quantbot Technologies LP acquired a new stake in Aveanna Healthcare during the 2nd quarter valued at approximately $43,000. MQS Management LLC purchased a new position in shares of Aveanna Healthcare during the 2nd quarter valued at approximately $59,000. Belvedere Trading LLC acquired a new stake in shares of Aveanna Healthcare during the second quarter worth approximately $62,000. Oxford Asset Management LLP bought a new stake in shares of Aveanna Healthcare in the second quarter worth $64,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Aveanna Healthcare in the second quarter valued at $68,000. Institutional investors and hedge funds own 87.96% of the company’s stock.

Key Stories Impacting Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Institutional buying in recent quarters — firms including Invesco, Millennium, Zimmer Partners and others increased or established positions in Q4, a vote of confidence that can support the stock over the medium term. MarketBeat Institutional Activity
• Positive Sentiment: Despite recent sales, insiders still retain large, multi?million?dollar stakes (CEO, CFO and others remain major shareholders), which can temper panic selling and signal some continued alignment with shareholders. SEC Filing
• Neutral Sentiment: Reported short interest shows zero shares for mid?February — this is almost certainly a reporting/data anomaly and does not indicate genuine lack of short interest. Treat the short?interest figure cautiously. Short Interest Data
• Neutral Sentiment: Trading volume today was below recent averages; low volume can amplify price moves when large blocks or news hit the tape (higher intraday volatility risk).
• Neutral Sentiment: Analyst coverage remains mixed: consensus is around a “Hold” with an average target near $11 — helpful context for longer?term positioning but not an immediate catalyst. Analyst Summary
• Negative Sentiment: Large, concentrated insider selling Feb. 17–19 by CEO Jeff Shaner — roughly 461,900 shares sold across three days (~$3.4M reported proceeds) — is the primary negative catalyst driving downward pressure as the market interprets sizeable CEO disposals as risk reduction. CEO Sales SEC Filing
• Negative Sentiment: Additional senior/executive selling (CFO Matthew Buckhalter, CAO Deborah Stewart, and other insiders including Edwin C. Reisz and Patrick A. Cunningham) involved hundreds of thousands of shares total across the same dates — a reinforcing negative signal that likely amplified the pullback. Other Insider Filings
• Negative Sentiment: Independent coverage singled out the insider selling as the main reason for a recent ~5–6% pullback, increasing market attention on the disposals and reinforcing short?term selling pressure. AAII Article

Analyst Ratings Changes

Several analysts recently issued reports on AVAH shares. Weiss Ratings reiterated a “hold (c+)” rating on shares of Aveanna Healthcare in a report on Monday, December 29th. BMO Capital Markets initiated coverage on Aveanna Healthcare in a research note on Thursday, November 13th. They issued an “outperform” rating and a $11.00 target price for the company. UBS Group raised their target price on Aveanna Healthcare from $9.50 to $10.00 and gave the company a “neutral” rating in a report on Thursday, January 15th. Royal Bank Of Canada upped their price target on Aveanna Healthcare from $10.00 to $11.00 and gave the stock a “sector perform” rating in a report on Thursday, January 15th. Finally, Truist Financial increased their price objective on shares of Aveanna Healthcare from $9.50 to $10.00 and gave the company a “hold” rating in a research report on Friday, November 7th. Five investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $11.06.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.